DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial

Sundar, R, Ng, A, Zouridis, H et al. (18 more authors) (2019) DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal of Cancer, 123. pp. 48-57. ISSN 0959-8049

Abstract

Metadata

Authors/Creators:
  • Sundar, R
  • Ng, A
  • Zouridis, H
  • Padmanabhan, N
  • Sheng, T
  • Zhang, S
  • Lee, MH
  • Ooi, WF
  • Qamra, A
  • Inam, I
  • Hewitt, LC
  • So, JB-Y
  • Koh, V
  • Nankivell, MG
  • Langley, RE
  • Allum, WH
  • Cunningham, D
  • Rozen, SG
  • Yong, WP
  • Grabsch, HI https://orcid.org/0000-0001-9520-6228
  • Tan, P
Copyright, Publisher and Additional Information: © 2019 Elsevier Ltd. All rights reserved. This is an author produced version of an article published in European Journal of Cancer. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: Epigenetic signature; DNA methylation; Predictive biomarker; Chemotherapy; Oesophageal adenocarcinoma
Dates:
  • Published: December 2019
  • Accepted: 16 September 2019
  • Published (online): 23 October 2019
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 17 Dec 2019 14:04
Last Modified: 23 Dec 2019 12:53
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.ejca.2019.09.016

Download

Accepted Version


Embargoed until: 23 October 2020

Filename: EJC-D-19-01385R1 (002).pdf

Licence: CC-BY-NC-ND 4.0

Request a copy

Share / Export

Statistics